TOP TEN perturbations for 1331_s_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1331_s_at
Selected probe(set): 219423_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1331_s_at (219423_x_at) across 6672 perturbations tested by GENEVESTIGATOR:

B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)

Relative Expression (log2-ratio):-3.4536896
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal T-cell; 20uM)
MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

kidney transplantation study 11 (1 week) / normal blood sample

Relative Expression (log2-ratio):-3.288291
Number of Samples:11 / 5
Experimental kidney transplantation study 11 (1 week)
Whole blood samples derived from kidney transplant patients 1 week post-transplantation. Samples were collected 1 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal blood sample
Blood samples derived from healthy control subjects.

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample

Relative Expression (log2-ratio):-3.13597
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal T-cell sample
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

kidney transplantation study 16 (2 week) / normal natural killer cell (CD56+) sample

Relative Expression (log2-ratio):-2.7867393
Number of Samples:3 / 3
Experimental kidney transplantation study 16 (2 week)
CD56+ natural killer cell samples derived from kidney transplant patients 2 weeks post-transplantation. Samples were collected 2 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal natural killer cell (CD56+) sample
CD56+ natural killer cell samples derived from healthy control subjects.

ovarian tumor study 11 (low grade) / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):2.6331959
Number of Samples:11 / 6
Experimental ovarian tumor study 11 (low grade)
Human microdissected tumor cells from the ovary of patients with low grade serous carcinoma.
Control normal ovarian surface epithelial cell sample
Human microdissected ovarian surface epithelial cell sample from the ovary of healthy individuals.

kidney transplantation study 11 (2 week) / normal blood sample

Relative Expression (log2-ratio):-2.52312
Number of Samples:9 / 5
Experimental kidney transplantation study 11 (2 week)
Whole blood samples derived from kidney transplant patients 2 weeks post-transplantation. Samples were collected 2 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal blood sample
Blood samples derived from healthy control subjects.

DLBCL study 7 (GCB; naive-like) / DLBCL study 7 (GCB; centroblast-like)

Relative Expression (log2-ratio):2.4779205
Number of Samples:2 / 9
Experimental DLBCL study 7 (GCB; naive-like)
Primary tumor samples from patients with diffuse large B-cell lymphoma (germinal center B-cell like type). Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS) and assigned to naive-like group. Patients were treated according to standard protocols, and comparable doses of RCHOP- like regimens were used. No patient was treated with stem cell transplantation.
Control DLBCL study 7 (GCB; centroblast-like)
Primary tumor samples from patients with diffuse large B-cell lymphoma (germinal center B-cell like type). Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS) and assigned to centroblast-like group. Patients were treated according to standard protocols, and comparable doses of RCHOP- like regimens were used. No patient was treated with stem cell transplantation.

small cell lung cancer study 4 (2. gen. PDX) / small cell lung cancer study 4 (2. gen. CDX)

Relative Expression (log2-ratio):-2.423399
Number of Samples:4 / 12
Experimental small cell lung cancer study 4 (2. gen. PDX)
Xenografts (secondary) tumor tissue samples derived from a PDX-derived cell lines. A patient derived xenograft (PDX)-derived cell lines were grown under conventional tissue culture conditions for six months and then reimplanted to generate secondary xenografts (2. gen.).
Control small cell lung cancer study 4 (2. gen. CDX)
Xenografts (secondary) tumor tissue samples derived from a CDX-derived cell lines. A cell line derived xenograft (CDX)-derived cell lines were grown under conventional tissue culture conditions for six months and then reimplanted to generate secondary xenografts (2. gen.).

sangivamycin study 1 / untreated MCF-7 cell sample

Relative Expression (log2-ratio):-2.4027119
Number of Samples:2 / 2
Experimental sangivamycin study 1
MCF7 cells treated with 2uM sangivamycin for 24 hours. ATC code:---
Control untreated MCF-7 cell sample
MCF-7 cells untreated.

gefitinib study 2 / wild type A431 cell sample

Relative Expression (log2-ratio):-2.3732119
Number of Samples:3 / 3
Experimental gefitinib study 2
Gefitinib-resistant A431 (A431 GR) cells generated by growing parental cells in the presence of increasing concentrations of gefitinib up to 3 μM. Cells were selected and maintained in gefitinib (3μM). ATC code:
Control wild type A431 cell sample
A431 wild type cells.